The second round of belt purchase direction has been set, Dabo pharmaceutical company will be out!

[industry trends of pharmaceutical network] the "4 + 7" volume purchase, which caused a sensation in the pharmaceutical industry, was officially launched in April this year In this context, the pharmaceutical industry presents a serious situation of oversupply In the process of market means and supervision, Dabo pharmaceutical enterprises will be out of the market, the number of participants in market competition will be reduced, the pattern of the pharmaceutical industry is expected to be reconstructed, and the enterprises with strength are expected to emerge According to the data statistics, as of July 18, the acceptance number of varieties passing and deemed passing the conformity evaluation of generic drugs reached 308, and the acceptance number of 225 varieties passing the conformity evaluation of generic drugs was deemed to pass 83 (subject to the catalogue set of Chinese listed drugs) Among them, there are 123 289 catalogue acceptance numbers, only 52 varieties In the first round of "4 + 7" belt purchase, only 25 products were sold and 100 products were involved According to the current conformity evaluation products, the industry believes that for the second round of "4 + 7" in fact, it has provided enough targets As for the drugs passing the consistency evaluation, as of July 18, there have been 24 enterprises passing the conformity evaluation, including rosuvastatin calcium tablets, amlodipine besylate tablets, montmorillonite powder, cefuroxime ester tablets, escitalopram oxalate tablets, Amoxicillin Capsules, tenofovir dipivoxil fumarate tablets, etc There are also 34 enterprises that have passed the regulations, and they are about to reach a tripartite confrontation There are varieties of dexmedetomidine, pemetrexed disodium, imatinib, flurbiprofen, enalapril, fosinopril, lisinopril, losartan potassium, montelukast, levetiracetam and so on that have been appraised by our family The second round of 4 + 7 city drug centralized procurement expansion ventilation meeting was held on August 15 The meeting stressed that to solve the price gap between pilot cities and non pilot cities will be an important goal of this round of work This also means that the expansion of regions (varieties) will be completed in succession For some varieties with more than three reviews, such as tenofovir, there are nine reviews, and the competition is very dangerous It is estimated that such a price war will become more and more fierce in the process of purchasing new tires Judging from the current situation, the general direction of the purchase of the second wheel belt quantity has been determined On July 29, the state health insurance bureau requested that the health insurance bureaus of all provinces except "4 + 7" cities, Fujian and Hebei collect the actual procurement data of 25 varieties in 2017 and 2018 At present, Hunan, Jiangsu, Anhui, Henan, Guangxi, etc have issued civilized and confirmed reports It can be seen that the pace of "4 + 7" nationwide promotion is accelerating and the details are gradually implemented According to the industry, the procurement of the second wheel belt may not expand the variety, with the bidding price of the first batch of belt procurement as the ceiling All the original research and generic pharmaceutical manufacturers that passed the consistency evaluation before the bid opening can participate in the bidding, and the "single bid winning mode" will be cancelled According to incomplete statistics, as of August 12, 12 of the 25 "4 + 7" varieties had newly added the evaluated enterprises compared with the first batch of volume purchasing In the face of large market cake and more and more competitors, many pharmaceutical companies take the initiative to reduce prices and seize the market It can be said that the purchase of the second wheel will make the competition in the pharmaceutical market more fierce, and a large number of pharmaceutical enterprises will be out at that time According to industry figures, there may be about 500 generic pharmaceutical manufacturers and a certain number of innovative enterprises with different scales remaining in China's drug supply market The total number of pharmaceutical manufacturers is about 1000.